Xenon Pharmaceuticals Inc. (XENE): Price and Financial Metrics


Xenon Pharmaceuticals Inc. (XENE): $34.62

0.18 (+0.52%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add XENE to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

XENE POWR Grades

  • Value is the dimension where XENE ranks best; there it ranks ahead of 43.94% of US stocks.
  • XENE's strongest trending metric is Momentum; it's been moving up over the last 177 days.
  • XENE's current lowest rank is in the Growth metric (where it is better than 3.54% of US stocks).

XENE Stock Summary

  • XENE's price/sales ratio is 234.2; that's higher than the P/S ratio of 98.49% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.03 for XENON PHARMACEUTICALS INC; that's greater than it is for just 6.42% of US stocks.
  • As for revenue growth, note that XENE's revenue has grown -48.83% over the past 12 months; that beats the revenue growth of merely 4.32% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to XENON PHARMACEUTICALS INC are INVZ, RAPT, AFMD, CARA, and ENTA.
  • XENE's SEC filings can be seen here. And to visit XENON PHARMACEUTICALS INC's official web site, go to www.xenon-pharma.com.

XENE Valuation Summary

  • XENE's price/sales ratio is 234.2; this is 4882.98% higher than that of the median Healthcare stock.
  • XENE's price/sales ratio has moved up 228.9 over the prior 102 months.

Below are key valuation metrics over time for XENE.

Stock Date P/S P/B P/E EV/EBIT
XENE 2023-03-24 234.2 3.1 -17.7 -17.3
XENE 2023-03-23 227.1 3.0 -17.2 -16.7
XENE 2023-03-22 224.2 2.9 -16.9 -16.5
XENE 2023-03-21 223.6 2.9 -16.9 -16.5
XENE 2023-03-20 231.2 3.0 -17.5 -17.0
XENE 2023-03-17 224.4 2.9 -16.9 -16.5

XENE Growth Metrics

    Its 4 year price growth rate is now at 234.22%.
  • The 2 year net income to common stockholders growth rate now stands at -122.99%.
  • Its year over year net income to common stockholders growth rate is now at -124.77%.
Over the past 33 months, XENE's revenue has gone up $6,342,000.

The table below shows XENE's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 13.171 -86.408 -112.756
2022-06-30 21.163 -71.013 -90.689
2022-03-31 22.845 -67.222 -81.119
2021-12-31 18.437 -69.502 -77.087
2021-09-30 19.85 -61.906 -63.985
2021-06-30 18.28 -58.053 -57.507

XENE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • XENE has a Quality Grade of D, ranking ahead of 7.55% of graded US stocks.
  • XENE's asset turnover comes in at 0.077 -- ranking 283rd of 681 Pharmaceutical Products stocks.
  • ADMP, ACUR, and ELTP are the stocks whose asset turnover ratios are most correlated with XENE.

The table below shows XENE's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.077 1 -0.353
2021-03-31 0.132 1 -0.233
2020-12-31 0.154 1 -0.194
2020-09-30 0.153 1 -0.197
2020-06-30 0.157 1 -0.237
2020-03-31 0.094 1 -0.381

XENE Price Target

For more insight on analysts targets of XENE, see our XENE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $27.88 Average Broker Recommendation 1.17 (Strong Buy)

XENE Stock Price Chart Interactive Chart >

Price chart for XENE

XENE Price/Volume Stats

Current price $34.62 52-week high $41.39
Prev. close $34.44 52-week low $24.94
Day low $33.24 Volume 414,600
Day high $34.79 Avg. volume 409,598
50-day MA $36.97 Dividend yield N/A
200-day MA $36.02 Market Cap 2.18B

Xenon Pharmaceuticals Inc. (XENE) Company Bio


Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing differentiated therapeutics for orphan indications in Canada. The company was founded in 1996 and is based in Burnaby, Canada.


XENE Latest News Stream


Event/Time News Detail
Loading, please wait...

XENE Latest Social Stream


Loading social stream, please wait...

View Full XENE Social Stream

Latest XENE News From Around the Web

Below are the latest news stories about XENON PHARMACEUTICALS INC that investors may wish to consider to help them evaluate XENE as an investment opportunity.

Xenon Pharmaceuticals to Present at the Stifel 2023 CNS Days

BURNABY, British Columbia, March 22, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the virtual Stifel 2023 CNS Days taking place March 28-29, 2023. Company Fireside Chat Presentation Details: Date:Tuesday, March 28, 2023 Time:1:00 pm Eastern Time (10:00 am Pacific Time) Presenters:Ian Mortimer, President and CEO Sherry Aulin, CFO Webcast: Link to pre-register for the webcast can b

Yahoo | March 22, 2023

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q4 2022 Earnings Call Transcript

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q4 2022 Earnings Call Transcript March 1, 2023 Operator: Ladies and gentlemen, thank you for standing by, and welcome to the Q4 2022 Xenon Pharmaceuticals, Inc. Earnings Conference Call. I would now like to turn the call over to Sherry Aulin, CFO. Please go ahead. Sherry Aulin: Good afternoon. Thank you […]

Yahoo | March 6, 2023

Xenon Pharmaceuticals Full Year 2022 Earnings: Revenues Disappoint

Xenon Pharmaceuticals ( NASDAQ:XENE ) Full Year 2022 Results Key Financial Results Net loss: US$124.9m (loss widened by...

Yahoo | March 4, 2023

We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Yahoo | March 2, 2023

Xenon Pharmaceuticals (XENE) Reports Q4 Loss, Lags Revenue Estimates

Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of 1.72% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | March 1, 2023

Read More 'XENE' Stories Here

XENE Price Returns

1-mo -10.54%
3-mo -11.62%
6-mo -4.10%
1-year 13.40%
3-year 214.73%
5-year 606.53%
YTD -12.20%
2022 26.22%
2021 103.12%
2020 17.32%
2019 107.77%
2018 123.36%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8108 seconds.